<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-85735" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pimavanserin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cusick</surname>
            <given-names>Erica</given-names>
          </name>
          <aff>Lake Erie College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Erica Cusick declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-85735.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Pimavanserin is a medication used to treat and manage the hallucinations and delusions associated with Parkinson disease psychosis. It is in the atypical antipsychotic class of drugs. This activity reviews the indication, action, and contraindications for pimavanserin as a valuable agent in managing Parkinson disease psychosis. This activity will highlight the mechanism of action, adverse event profile, dosing, monitoring, relevant interactions, and other key factors pertinent for healthcare team members in the care of patients with Parkinson disease psychosis.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for pimavanserin.</p></list-item><list-item><p>Review the typical adverse effects of pimavanserin.</p></list-item><list-item><p>Summarize the risks associated with initiating pimavanserin, summarizing key patient counseling points.</p></list-item><list-item><p>Outline the importance of collaboration and coordination among the interprofessional team to enhance patient care when initiating and monitoring pimavanserin to improve patient outcomes for patients receiving treatment for Parkinson disease psychosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=85735&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=85735">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-85735.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Pimavanserin is an atypical antipsychotic that received FDA approval in the U.S. in 2016 for hallucinations and delusions that accompany Parkinson disease psychosis (PDP).<xref ref-type="bibr" rid="article-85735.r1">[1]</xref>&#x000a0;It is the first and only FDA-approved medication for PDP. It had initially received Breakthrough Therapy status from the FDA in 2014. In&#x000a0;the phase III clinical trial that paved the way for FDA approval, patients receiving pimavanserin demonstrated significant improvement in&#x000a0;the frequency and/or severity of hallucinations and/or delusions&#x000a0;without worsening motor function compared to patients receiving a placebo.<xref ref-type="bibr" rid="article-85735.r2">[2]</xref>&#x000a0;A separate study using data from the same trial found a more robust response to pimavanserin in PDP patients with impaired cognitive functioning.<xref ref-type="bibr" rid="article-85735.r3">[3]</xref>&#x000a0;Besides its use in PDP, pimavanserin has no other FDA or non-FDA-approved indications. However, there are various ongoing studies on the potential uses of pimavanserin.</p>
        <p>In addition to Parkinson disease, psychotic symptoms can also&#x000a0;manifest in different subtypes of dementia. At present, there are no FDA-approved agents indicated for&#x000a0;dementia-related psychosis (DRP). Pimavanserin is under evaluation for its potential use in DRP.<xref ref-type="bibr" rid="article-85735.r4">[4]</xref>&#x000a0;In a phase II clinical trial of patients with Alzheimer disease psychosis, patients treated with pimavanserin versus placebo showed significant improvement in psychosis at the 6-week primary endpoint (p=0&#x000b7;045). The significance did not progress to the week 12 follow-up (p=0&#x000b7;561).<xref ref-type="bibr" rid="article-85735.r5">[5]</xref>&#x000a0;Notably, there was no observable&#x000a0;negative impact on cognition in either group.<xref ref-type="bibr" rid="article-85735.r5">[5]</xref>&#x000a0;Further evaluation of a severe subgroup of patients with Alzheimer disease psychosis demonstrated more significant improvement of symptoms.<xref ref-type="bibr" rid="article-85735.r6">[6]</xref>&#x000a0;</p>
        <p>In a study examining the discontinuation rate of patients with PDP or dementia with Lewy bodies (DLB) given either pimavanserin or quetiapine, the discontinuation rate of patients treated with pimavanserin was lower earlier on and higher later on in comparison to quetiapine.<xref ref-type="bibr" rid="article-85735.r7">[7]</xref>&#x000a0;Outside of the realm of DRP, pimavanserin has also shown promise in treating positive as well as challenging to treat negative symptoms of schizophrenia. A recent study reported success with pimavanserin in patients with schizophrenia and schizoaffective disorder with refractory psychosis.<xref ref-type="bibr" rid="article-85735.r8">[8]</xref>&#x000a0;The manufacturer of the drug reported that as of March 2022, they were conducting a phase 3 clinical trial to evaluate pimavanserin for major depressive disorder and schizophrenia, as well as phase 2&#x000a0;trials for agitation and phase 1 trials examining its effectiveness in psychiatric disorders.<xref ref-type="bibr" rid="article-85735.r9">[9]</xref><xref ref-type="bibr" rid="article-85735.r10">[10]</xref></p>
        <p>Researchers further observed that there was a consequential improvement&#x000a0;in social functioning and negative symptoms.<xref ref-type="bibr" rid="article-85735.r8">[8]</xref>&#x000a0;Pimavanserin has also shown considerable promise as an adjunctive treatment in patients with major depressive disorder (MDD) refractory to SSRI and SNRI medications alone.<xref ref-type="bibr" rid="article-85735.r11">[11]</xref>&#x000a0;It may also have implications in treating insomnia as it has been shown to significantly increase slow-wave sleep and decrease the frequency of nighttime awakenings.<xref ref-type="bibr" rid="article-85735.r12">[12]</xref></p>
      </sec>
      <sec id="article-85735.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Pimavanserin is an antagonist/inverse agonist at the 5HT2A receptor and has a 40-fold weaker antagonism/inverse agonism at the 5HT2C receptor.<xref ref-type="bibr" rid="article-85735.r13">[13]</xref>&#x000a0;Unlike other atypical antipsychotics, pimavanserin&#x000a0;lacks dopaminergic activity, namely at the D2 receptor. Pimavanserin is the first drug without dopamine D2 blocking activity that displays antipsychotic actions. Thus, fulfilling a particular niche by treating the psychotic symptoms without worsening the motor symptoms of parkinsonism,&#x000a0;an adverse effect commonly observed with other antipsychotics.<xref ref-type="bibr" rid="article-85735.r2">[2]</xref>&#x000a0;Additionally, pimavanserin does not cause sedation, seen in quetiapine or clozapine, which are currently used off-label to treat PDP.<xref ref-type="bibr" rid="article-85735.r2">[2]</xref></p>
        <p>Pimavanserin metabolism primarily occurs in the liver; it is a CYP450 enzyme-substrate, primarily CYP3A4/5, but also CYP2D6 and CYP2J2. It has an active metabolite. The drug has a half-life of 57 hours for the parent drug and 200 hours for the active metabolite. It is excreted in the urine and feces.</p>
      </sec>
      <sec id="article-85735.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The recommended dose for Parkinson disease-associated psychosis is 34 mg orally once daily. Pimavanserin is only available for oral administration. Patients may take pimavanserin with or without food. Titration is not required. It is only available as an immediate-release formulation. No significant drug interactions with carbidopa/levodopa have been observed, and therefore, no dosage adjustments are necessary.<xref ref-type="bibr" rid="article-85735.r14">[14]</xref>&#x000a0;</p>
        <p>As mentioned above, pimavanserin undergoes significant hepatic metabolization by CYP450 3A4 and 3A5. Thus, the recommendation is to reduce when co-administered with a potent&#x000a0;CYP3A4 inhibitor (i.e., itraconazole, ketoconazole, clarithromycin, indinavir)&#x000a0;pimavanserin dose by 50%. In contrast, when given in the presence of a strong CYP450 34A and 3A5 inducer (for example, rifampin, carbamazepine, phenytoin, and St. John&#x02019;s wort), providers should monitor for reduced efficacy and increase the pimavanserin dose as needed.<xref ref-type="bibr" rid="article-85735.r15">[15]</xref></p>
        <p>Pimavanserin requires no renal dosing adjustment, although clinicians should exercise caution for patients with a creatinine clearance below 30. Peritoneal and hemodialysis dosing are undefined.&#x000a0;</p>
        <p>Pimavanserin has no pediatric dosing or indications.</p>
      </sec>
      <sec id="article-85735.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>In the controlled trial setting, common adverse effects at an incidence of 5% or more included peripheral edema, confusional state, and nausea. Adverse reactions at an incidence of 2% or greater included hallucinations, peripheral edema, nausea, confusion, constipation, and gait disturbances. Instances in which&#x000a0;treatment was discontinued in patients treated with pimavanserin (8%), as well as patients treated with placebo (4%), included&#x000a0;hallucinations (2% pimavanserin 34 mg versus less than 1% placebo), urinary tract infection (1% pimavanserin 34 mg&#x000a0;versus less than 1% placebo), and fatigue (1% pimavanserin 34 mg&#x000a0;versus 0% placebo).<xref ref-type="bibr" rid="article-85735.r16">[16]</xref>&#x000a0;</p>
        <p>As&#x000a0;is the case with other antipsychotics, pimavanserin may cause QTc prolongation; this raises concern as it could potentially lead to the life-threatening tachyarrhythmia called torsades de pointes.<xref ref-type="bibr" rid="article-85735.r17">[17]</xref>&#x000a0;Another potentially severe adverse reaction is angioedema.</p>
        <p>While the mechanism of action of pimavanserin differs from other atypical antipsychotics, namely the resulting lack of dopamine D2 receptor blockade, there is a remaining concern for the risk of death in elderly patients with dementia-related psychosis&#x000a0;since pimavanserin could potentially have a similar effect. Therefore, like other antipsychotics, pimavanserin has a black box warning&#x000a0;of increased mortality in&#x000a0;elderly patients with dementia-related psychosis. Pimavanserin is safe to use in patients with mild to moderate renal impairment, and dosage adjustment is not required. Pimavanserin is not recommended for use in patients with severe renal impairment or any degree of hepatic impairment.<xref ref-type="bibr" rid="article-85735.r16">[16]</xref></p>
      </sec>
      <sec id="article-85735.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to taking pimavanserin include&#x000a0;hypersensitivity to pimavanserin or any of its constituents. Other contraindications or cautions include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Uncorrected electrolyte abnormalities</p>
          </list-item>
          <list-item>
            <p>QT prolongation or a family history of QT prolongation, including congenital long QT syndrome</p>
          </list-item>
          <list-item>
            <p>A history of torsades des pointes</p>
          </list-item>
          <list-item>
            <p>Ventricular arrhythmias</p>
          </list-item>
          <list-item>
            <p>Recent history of myocardial infarct</p>
          </list-item>
          <list-item>
            <p>Bradycardia</p>
          </list-item>
          <list-item>
            <p>Congestive heart failure</p>
          </list-item>
        </list>
        <p>Caution is also recommended in the elderly, patients with end-stage renal disease (ESDRD) or a CrCl below 30, and patients with psychosis related to dementia.</p>
        <p>There is presently no human data regarding the use of pimavanserin in pregnancy; clinicians need to weigh the risk vs. benefit in this patient population; animal studies showed no teratogenicity at&#x000a0;ten times the maximum recommended human dose (MRHD). Similarly, clinicians should weigh the risk vs. benefit in breastfeeding patients; there is no data available to assess the drug's effect on milk production or the risk of infant harm.</p>
        <p>Contraindicated drug interactions include concomitant use with pimozide or thioridazine. As already discussed, caution and dosing adjustments may be necessary with potent CYP450 inducers and inhibitors.</p>
      </sec>
      <sec id="article-85735.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Pimavanserin may cause QTc prolongation. Patients should receive instructions to report any new onset palpitations, syncope, or near-syncope. Likewise, clinical illnesses such as gastroenteritis or the initiation of diuretic therapy, which could lead to hypokalemia, should also be reported as prompt identification and correction of electrolyte abnormalities minimizes the risk of arrhythmias. Pimanversin is not associated with the constellation of weight gain, hyperlipidemia, and hyperglycemia, called metabolic syndrome seen in other atypical antipsychotics. However, it is still beneficial for the patient to eat a healthy diet, engage in an exercise regimen, and abstain from or stop smoking while taking the medication. Given that pimavanserin undergoes hepatic metabolization via the same&#x000a0;cytochrome&#x000a0;P450 pathways as various other medications, providers should be aware of drugs that may&#x000a0;inhibit or induce&#x000a0;the metabolism of pimavanserin and adjust dosing accordingly.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-85735.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There have been no reported overdoses to date, and there is no specific antidote for pimavanserin.&#x000a0;</p>
      </sec>
      <sec id="article-85735.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Care&#x000a0;is necessary across the&#x000a0;interprofessional spectrum to ensure proper medication safety, efficacy, and adherence. The prescribing clinician should continually monitor and educate the patient on the risks and benefits of pimavanserin; it may be beneficial to consult with a geriatric or psychiatric Board of Pharmacy specialty pharmacist. All pharmacists involved in patient care&#x000a0;need to be alert&#x000a0;for changes in the patient's medications that may lead to drug interactions with pimavanserin and be prepared to make recommendations to change the patient's drug regimen if necessary.</p>
        <p>In long-term care, nursing home, or home care settings, nursing staff can continually monitor patients for the common and&#x000a0;life-threatening adverse effects of pimavanserin and either consult with the pharmacist or report their observations to the prescribing clinician immediately. Nursing staff can also monitor patient compliance and provide educational support to patients. As pimavanserin is a newer medication, other specialists working with the patient can familiarize themselves with the side effects and drug interactions of pimavanserin.</p>
        <p>Lastly, pimavanserin is expensive.&#x000a0;In patients that would benefit from pimavanserin, the prescribing clinician, social workers, insurance companies, and other staff members can work together to make pimavanserin accessible, as affordability is a concern that must be addressed, even if pimavanserin is the optimal therapeutic agent for a particular patient case. These types of interprofessional team&#x000a0;interactions are but a few examples of how the interprofessional team model should work, which&#x000a0;can lead to more successful outcomes with pimavanserin. [Level 5]&#x000a0;</p>
      </sec>
      <sec id="article-85735.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=85735&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=85735">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/85735/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=85735">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-85735.s11">
        <title>References</title>
        <ref id="article-85735.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hawkins</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Pimavanserin: A novel therapeutic option for Parkinson disease psychosis.</article-title>
            <source>Neurol Clin Pract</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-162</page-range>
            <pub-id pub-id-type="pmid">29185542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85735.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cummings</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Isaacson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chi-Burris</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Corbett</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dhall</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ballard</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2014</year>
            <month>Feb</month>
            <day>08</day>
            <volume>383</volume>
            <issue>9916</issue>
            <fpage>533</fpage>
            <page-range>533-40</page-range>
            <pub-id pub-id-type="pmid">24183563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85735.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Espay</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Guskey</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Norton</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Coate</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vizcarra</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ballard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Factor</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fredericks</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weintraub</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.</article-title>
            <source>Mov Disord</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>11</issue>
            <fpage>1769</fpage>
            <page-range>1769-1776</page-range>
            <pub-id pub-id-type="pmid">30387904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85735.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cummings</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ballard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tariot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Foff</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Youakim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Norton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stankovic</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pimavanserin: Potential Treatment For Dementia-Related Psychosis.</article-title>
            <source>J Prev Alzheimers Dis</source>
            <year>2018</year>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>253</fpage>
            <page-range>253-258</page-range>
            <pub-id pub-id-type="pmid">30298184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85735.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ballard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Banister</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Cummings</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Demos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Coate</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Youakim</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stankovic</surname>
                <given-names>S</given-names>
              </name>
              <collab>ADP Investigators</collab>
            </person-group>
            <article-title>Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.</article-title>
            <source>Lancet Neurol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>213</fpage>
            <page-range>213-222</page-range>
            <pub-id pub-id-type="pmid">29452684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85735.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ballard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Youakim</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Coate</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stankovic</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms.</article-title>
            <source>J Prev Alzheimers Dis</source>
            <year>2019</year>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-33</page-range>
            <pub-id pub-id-type="pmid">30569083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85735.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>SX</given-names>
              </name>
              <name>
                <surname>Weintraub</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dahodwala</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.</article-title>
            <source>Parkinsonism Relat Disord</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>69</volume>
            <fpage>119</fpage>
            <page-range>119-124</page-range>
            <pub-id pub-id-type="pmid">31751863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85735.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasrallah</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Fedora</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Morton</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.</article-title>
            <source>Schizophr Res</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>208</volume>
            <fpage>217</fpage>
            <page-range>217-220</page-range>
            <pub-id pub-id-type="pmid">30837203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85735.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bugarski-Kirola</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Arango</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fava</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nasrallah</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>IY</given-names>
              </name>
              <name>
                <surname>Abbs</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stankovic</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.</article-title>
            <source>Lancet Psychiatry</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>46</fpage>
            <page-range>46-58</page-range>
            <pub-id pub-id-type="pmid">34861170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85735.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crump</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Litteral</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Elsayed</surname>
                <given-names>OH</given-names>
              </name>
              <name>
                <surname>El-Mallakh</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Pimavanserin for bipolar disorder.</article-title>
            <source>Bipolar Disord</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>697</fpage>
            <page-range>697-699</page-range>
            <pub-id pub-id-type="pmid">35167172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85735.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fava</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dirks</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Papakostas</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Shelton</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Thase</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stankovic</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY).</article-title>
            <source>J Clin Psychiatry</source>
            <year>2019</year>
            <month>Sep</month>
            <day>24</day>
            <volume>80</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">31556975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85735.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ancoli-Israel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vanover</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>van Kammen</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers.</article-title>
            <source>Sleep Med</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>134</fpage>
            <page-range>134-41</page-range>
            <pub-id pub-id-type="pmid">21256805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85735.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanover</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Makhay</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Veinbergs</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gardell</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Lameh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Del Tredici</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Piu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schiffer</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Ott</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Burstein</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Uldam</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Thygesen</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Schlienger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Son</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Harvey</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Geyer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Tolf</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Brann</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>2006</year>
            <month>May</month>
            <volume>317</volume>
            <issue>2</issue>
            <fpage>910</fpage>
            <page-range>910-8</page-range>
            <pub-id pub-id-type="pmid">16469866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85735.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meltzer</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.</article-title>
            <source>J Clin Invest</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>123</volume>
            <issue>12</issue>
            <fpage>4986</fpage>
            <page-range>4986-91</page-range>
            <pub-id pub-id-type="pmid">24292660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85735.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Bhela</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tahir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pisati</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Hossain</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pimavanserin in Parkinson's Disease-induced Psychosis: A Literature Review.</article-title>
            <source>Cureus</source>
            <year>2019</year>
            <month>Jul</month>
            <day>28</day>
            <volume>11</volume>
            <issue>7</issue>
            <fpage>e5257</fpage>
            <pub-id pub-id-type="pmid">31572642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85735.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cruz</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Pimavanserin (Nuplazid): A Treatment for Hallucinations and Delusions Associated With Parkinson's Disease.</article-title>
            <source>P T</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>368</fpage>
            <page-range>368-371</page-range>
            <pub-id pub-id-type="pmid">28579723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-85735.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Aftab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Coverdale</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>QTc prolongation with antipsychotics: is routine ECG monitoring recommended?</article-title>
            <source>J Psychiatr Pract</source>
            <year>2014</year>
            <month>May</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>196</fpage>
            <page-range>196-206</page-range>
            <pub-id pub-id-type="pmid">24847993</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
